inositol niacinate profile

Inositol niacinate, also known as inositol hexanicotinate, is a compound formed by combining inositol with six molecules of nicotinic acid (niacin). It is a naturally occurring compound found in small amounts in some foods. Research suggests that inositol niacinate may offer benefits for cardiovascular health, including lowering cholesterol levels, improving blood flow, and reducing the risk of blood clots. It is also being studied for its potential to improve cognitive function and reduce inflammation. The mechanism of action of inositol niacinate is thought to involve its ability to act as a precursor to nicotinamide adenine dinucleotide (NAD+), a crucial coenzyme involved in numerous metabolic processes. Unlike niacin, inositol niacinate does not cause flushing, a common side effect of niacin supplementation. It is believed to be safer for long-term use compared to niacin. Further research is needed to fully understand its benefits and potential applications in health and disease.'

ID Source	ID
PubMed CID	3720
CHEMBL ID	1094982
CHEBI ID	33064
CHEBI ID	31699
SCHEMBL ID	122590
SCHEMBL ID	122591
SCHEMBL ID	13557040
MeSH ID	M0046559

Synonym
nsc-49506
mesotal
nsc49506
inositol niacinate
hamovannad
nicotinic acid, with 1,2-trans, 3-cis, 4-trans, 5-cis, 6-cis-cyclohexanehexol
dilexpal
cyclohexane-1,2,3,4,5,6-hexayl hexapyridine-3-carboxylate
nsc 49506
hexanicit
hexanicotol
hexopal
inositolo nicotinato [dcit]
esantene
win 9154
inositol niacinate [usan]
dilcit
brn 0077649
inositoli nicotinas [inn-latin]
inositol nicotinate
myo-inositol, hexa-3-pyridinecarboxylate
nicotinate d'inositol [inn-french]
nicotinato de inositol
1,2,3,54,6 cyclohexanehexol hexanicotinate
nicotinato de inositol [inn-spanish]
inositol, hexanicotinate, myo-
1,2,3,5/4,6 cyclohexanehexol hexanicotinate
linodil
einecs 229-485-9
palohex
mesonex
inositol hexanicotinate
cyclohexane-1,2,3,4,5,6-hexayl hexanicotinate
(1r,2r,3s,4s,5r,6s)-cyclohexane-1,2,3,4,5,6-hexayl hexanicotinate
6556-11-2
CHEBI:33064
CHEBI:31699 ,
hexanicotinoyl inositol
myo-inositol hexanicotinate
nsc81283
nsc-81283
[2,3,4,5,6-pentakis(pyridine-3-carbonyloxy)cyclohexyl] pyridine-3-carboxylate
nicotinic acid, ester, with 1,2-trans, 3-cis, 4-trans, 5-cis, 6-cis-cyclohexanehexol
2,3,4,5,6-pentakis((3-pyridinylcarbonyl)oxy)cyclohexyl nicotinate
D01813
inositol hexanicotinate (jan)
inositol nicotinate (inn)
inositol niacinate (usan)
palohex (tn)
hamovannid
CHEMBL1094982
win-9154
inositoli nicotinas
AKOS015951374
AKOS015960653
nicotinate d'inositol
3-pyridinecarboxylic acid, 1,2,3,4,5,6-cyclohexanehexayl ester
unii-a99mk953kz
inositol nicotinate [inn]
a99mk953kz ,
5-22-02-00067 (beilstein handbook reference)
inositolo nicotinato
FT-0627239
FT-0627238
inositol nicotinate [who-dd]
inositol hexanicotinate [jan]
inositol nicotinate [mart.]
inositol niacinate [mi]
S4987
SCHEMBL122590
SCHEMBL122591
SCHEMBL13557040
497820-05-0
DTXSID2023147
AC-8131
SR-01000883744-1
sr-01000883744
myo-inosithexanicotinat
DB08949
mesoinositol hexanicotinate
Q6036641
mfcd00006387
AS-13351
rel-(1r,2r,3s,4r,5s,6s)-cyclohexane-1,2,3,4,5,6-hexayl hexanicotinate
BRD-K00566342-001-01-0
(1r,2r,3s,4r,5s,6s)-cyclohexane-1,2,3,4,5,6-hexayl hexanicotinate
inositol-hexanicotinate
NCGC00532507-01
D70660
A914042
rel-(1r,2r,3s,4r,5s,6s)-cyclohexane-1,2,3,4,5,6-hexaylhexanicotinate
CS-0084450
HY-122365
DTXSID10859980
EN300-19997221
(1r,2r,3s,4s,5r,6s)-2,3,4,5,6-pentakis(pyridine-3-carbonyloxy)cyclohexyl pyridine-3-carboxylate

Excerpt	Reference	Relevance
" Pharmacokinetics demonstrated an intermediate release and absorption rate for WMER over 6 hours and IHN showed no evidence of bioavailability."	( Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia. Keenan, JM, )	0.13
"Inositol hexanicotinate (IHN) self-micelle solid dispersion (SD) with glycyrrhizic acid (GA) and arabic gum (AG) was prepared by mechanical ball milling process to improve the solubility, stability of amorphous state, and bioavailability of IHN, which enhanced the treatment of IHN on hyperlipidemia and nonalcoholic fatty liver disease (NAFLD)."	( Inositol hexanicotinate self-micelle solid dispersion is an efficient drug delivery system in the mouse model of non-alcoholic fatty liver disease. Dushkin, AV; Su, W; Sun, C; Xu, W; Yu, J; Zhang, Q; Zheng, L; Zhu, X, 2021)	0.62

Excerpt	Relevance	Reference
" Blood chemistries showed small (24%-27%) mean increases in hepatic transaminases; six subjects completed the study at reduced dosage protocol with good lipid results."	( Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia. Keenan, JM, )	0.13

Product Category	Products
Vitamins & Supplements	5

Product	Brand	Category	Compounds Matched from Ingredients	Date Retrieved
Bluebonnet Nutrition CellularActive® Coenzyme B-Complex -- 100 Vcaps®	Bluebonnet Nutrition	Vitamins & Supplements	PABA, Biotin, Choline, riboflavin 5' phosphate, inositol hexanicotinate, Inositol, Vitamin B3, niacinamide, PABA, Pantothenic Acid, pyridoxal 5' phosphate, pyridoxine HCl, Vitamin B6, Vitamin B2, cocarboxylase, Vitamin B1, Vitamin B12, Vitamin B6	2024-11-29 10:47:42
Country Life Core Daily-1 for Men 50 + -- 60 Tablets	Country Life	Vitamins & Supplements	Lipase, Vitamin C, beta carotene, Betaine, Biotin, Calcium fructoborate, d-calcium pantothenate, Cellulase, Choline, Chromium, Vitamin E, riboflavin 5' phosphate, Folic Acid, Vitamin E, inositol hexanicotinate, Inositol, Lactose, Manganese, Molybdenum, Niacin, pantethine, Pantothenic Acid, Phosphorus, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, citrate, citrate, thiamine hydrochloride, Thiamin, cyanocobalamin, Vitamin B6, Vitamin K	2024-11-29 10:47:42
Country Life Core Daily™ 1 for Women 50 Plus -- 60 Tablets	Country Life	Vitamins & Supplements	Lipase, Vitamin C, beta carotene, Betaine, Biotin, Calcium fructoborate, d-calcium pantothenate, Cellulase, Choline, Chromium, Vitamin E, riboflavin 5' phosphate, Folic Acid, Vitamin E, inositol hexanicotinate, Inositol, Lactose, Manganese, Molybdenum, Niacin, pantethine, Pantothenic Acid, Phosphorus, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, citrate, citrate, thiamine hydrochloride, Thiamin, cyanocobalamin, Vitamin B6, Vitamin K	2024-11-29 10:47:42
Country Life Daily Total One™ Iron Free -- 60 Vegetarian Capsules	Country Life	Vitamins & Supplements	ascorbyl palmitate, Vitamin C, beta carotene, Betaine, Biotin, Boron, calcium ascorbate, calcium citrate, d-calcium pantothenate, di-calcium phosphate, Chromium, Vitamin E, riboflavin 5' phosphate, Folate, Vitamin E, inositol hexanicotinate, Inositol, magnesium citrate, Manganese, Molybdenum, Niacin, niacinamide, pantethine, Pantothenic Acid, Phosphorus, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, retinyl palmitate, Vitamin A, Riboflavin, Selenium, thiamine hydrochloride, Thiamin, Vitamin B12, Vitamin B6, Vitamin K	2024-11-29 10:47:42
Vitacost-Synergy Optimized B-100 Complex Enhanced Absorption -- 60 Capsules	Vitacost-Synergy	Vitamins & Supplements	Biotin, Choline, riboflavin 5'-phosphate, Folate, inositol hexanicotinate, Inositol, Niacin, niacinamide, Pantothenic Acid, pyridoxal 5-phosphate, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B6	2024-11-29 10:47:42

Class	Description
inositol nicotinate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Assay ID	Title	Year	Journal	Article
AID480091	Hypolipidemic activity in high fat diet-fed C57BL/6 mouse assessed as decrease in plasma total cholesterol level at 200 mg/kg, ig administered QD for 4 weeks	2010	Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9	Synthesis and biological evaluation of isoflavone fatty acid esters with potential weight loss and hypolipidemic activities.
AID480095	Hypolipidemic activity in high fat diet-fed C57BL/6 mouse assessed as increase in plasma HDL level at 200 mg/kg, ig administered QD for 4 weeks	2010	Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9	Synthesis and biological evaluation of isoflavone fatty acid esters with potential weight loss and hypolipidemic activities.
AID480093	Hypolipidemic activity in high fat diet-fed C57BL/6 mouse assessed as decrease in plasma LDL level at 200 mg/kg, ig administered QD for 4 weeks	2010	Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9	Synthesis and biological evaluation of isoflavone fatty acid esters with potential weight loss and hypolipidemic activities.
AID480089	Hypolipidemic activity in high fat diet-fed C57BL/6 mouse assessed as decrease in plasma triglyceride level at 200 mg/kg, ig administered QD for 4 weeks	2010	Bioorganic & medicinal chemistry, May-01, Volume: 18, Issue:9	Synthesis and biological evaluation of isoflavone fatty acid esters with potential weight loss and hypolipidemic activities.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	29 (74.36)	18.7374
1990's	1 (2.56)	18.2507
2000's	3 (7.69)	29.6817
2010's	5 (12.82)	24.3611
2020's	1 (2.56)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	8 (19.51%)	5.53%
Reviews	2 (4.88%)	6.00%
Case Studies	1 (2.44%)	4.05%
Observational	0 (0.00%)	0.25%
Other	30 (73.17%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	1.95	1	0	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
inositol Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.. inositol : Any cyclohexane-1,2,3,4,5,6-hexol.. 1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.. muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.	11.24	20	2	cyclitol; hexol
niacin Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.	4.02	15	0	pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3	antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent
pyridoxine 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source. vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).	1.93	1	0	hydroxymethylpyridine; methylpyridines; monohydroxypyridine; vitamin B6	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cilostazol [no description available]	3.16	1	0	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	2.36	2	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clofibric acid Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.. clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.	2.36	2	0	aromatic ether; monocarboxylic acid; monochlorobenzenes	anticholesteremic drug; antilipemic drug; antineoplastic agent; herbicide; marine xenobiotic metabolite; PPARalpha agonist
mefruside Mefruside: A benzene-sulfonamide-furan. It is used as a diuretic that affects the concentrating ability of the KIDNEY, increases SODIUM CHLORIDE excretion, but may not spare POTASSIUM. It inhibits CARBONIC ANHYDRASES and may increase the blood URIC ACID level.	3.34	1	1	organic molecular entity
nafronyl Nafronyl: A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.	4.12	2	0	naphthalenes
niceritrol Niceritrol: An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions.	1.95	1	0	organic molecular entity
pentoxifylline [no description available]	4.12	2	0	oxopurine
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	2.05	1	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
sibutramine sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride	2.05	1	0	organochlorine compound; tertiary amino compound	anti-obesity agent; serotonin uptake inhibitor
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	3.34	1	1	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
nicotinyl alcohol Nicotinyl Alcohol: Alcohol analog of NICOTINIC ACID which is a direct-acting peripheral vasodilator that causes flushing and may decrease blood pressure. It is used in vasospasm and threatened GANGRENE.. 3-pyridinemethanol : A member of the class of pyridines that is pyridine which is substituted by a hydroxymethyl group at position 3 .	1.95	1	0	aromatic primary alcohol; pyridines	antilipemic drug; vasodilator agent
xanthinol niacinate Xanthinol Niacinate: A vasodilator used in peripheral vascular disorders and insufficiency. It may cause gastric discomfort and hypotension.	2.36	2	0
bezafibrate [no description available]	2.36	2	0	aromatic ether; monocarboxylic acid amide; monocarboxylic acid; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
formononetin [no description available]	2.05	1	0	4'-methoxyisoflavones; 7-hydroxyisoflavones	phytoestrogen; plant metabolite
alprostadil [no description available]	3.27	1	0	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
iloprost Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.. iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension.	3.27	1	0	carbobicyclic compound; monocarboxylic acid; secondary alcohol	platelet aggregation inhibitor; vasodilator agent
cardiovascular agents Cardiovascular Agents: Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.	1.93	1	0

Condition	Relationship Strength	Studies	Trials
Weight Reduction [description not available]	2.05	1	0
Weight Loss Decrease in existing BODY WEIGHT.	2.05	1	0
Fatty Liver, Nonalcoholic [description not available]	2.31	1	0
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	2.31	1	0
Leg Ulcer Ulceration of the skin and underlying structures of the lower extremity. About 90% of the cases are due to venous insufficiency (VARICOSE ULCER), 5% to arterial disease, and the remaining 5% to other causes.	3.09	1	0
Diseases, Peripheral Vascular [description not available]	4.11	6	0
Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.	3.3	2	0
Peripheral Vascular Diseases Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.	4.11	6	0
Hyperlipemia [description not available]	2.43	2	0
Hyperlipidemias Conditions with excess LIPIDS in the blood.	2.43	2	0
Peripheral Arterial Diseases [description not available]	3.29	2	0
Intermittent Claudication A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE.	6.71	6	4
Peripheral Arterial Disease Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less.	3.29	2	0
Vascular Diseases Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.	3.44	8	0
ANS (Autonomic Nervous System) Diseases [description not available]	1.93	1	0
Brain Vascular Disorders [description not available]	2.34	2	0
Neuritis A general term indicating inflammation of a peripheral or cranial nerve. Clinical manifestation may include PAIN; PARESTHESIAS; PARESIS; or HYPESTHESIA.	1.93	1	0
Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.	2.34	2	0
Pulsatile Tinnitus [description not available]	1.93	1	0
Tinnitus A nonspecific symptom of hearing disorder characterized by the sensation of buzzing, ringing, clicking, pulsations, and other noises in the ear. Objective tinnitus refers to noises generated from within the ear or adjacent structures that can be heard by other individuals. The term subjective tinnitus is used when the sound is audible only to the affected individual. Tinnitus may occur as a manifestation of COCHLEAR DISEASES; VESTIBULOCOCHLEAR NERVE DISEASES; INTRACRANIAL HYPERTENSION; CRANIOCEREBRAL TRAUMA; and other conditions.	1.93	1	0
Craniocerebral Injuries [description not available]	1.93	1	0
Craniocerebral Trauma Traumatic injuries involving the cranium and intracranial structures (i.e., BRAIN; CRANIAL NERVES; MENINGES; and other structures). Injuries may be classified by whether or not the skull is penetrated (i.e., penetrating vs. nonpenetrating) or whether there is an associated hemorrhage.	1.93	1	0
Liver Dysfunction [description not available]	1.94	1	0
Liver Diseases Pathological processes of the LIVER.	1.94	1	0
Coronary Heart Disease [description not available]	1.94	1	0
Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.	1.94	1	0
Arteriosclerosis Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.	1.93	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.01	1	0
Weight Gain Increase in BODY WEIGHT over existing weight.	2.01	1	0
Chronic Illness [description not available]	3.34	1	1
Cerebral Ischemia [description not available]	3.34	1	1
Cerebral Arteriosclerosis [description not available]	3.34	1	1
Intracranial Arteriosclerosis Vascular diseases characterized by thickening and hardening of the walls of ARTERIES inside the SKULL. There are three subtypes: (1) atherosclerosis with fatty deposits in the ARTERIAL INTIMA; (2) Monckeberg's sclerosis with calcium deposits in the media and (3) arteriolosclerosis involving the small caliber arteries. Clinical signs include HEADACHE; CONFUSION; transient blindness (AMAUROSIS FUGAX); speech impairment; and HEMIPARESIS.	3.34	1	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	3.34	1	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	3.34	1	1
Apolipoprotein B-100, Familial Defective [description not available]	2.36	2	0
Hyperlipoproteinemia Type II A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).	2.36	2	0
Cold Fingers, Hereditary [description not available]	4.04	3	1
Raynaud Disease An idiopathic vascular disorder characterized by bilateral Raynaud phenomenon, the abrupt onset of digital paleness or CYANOSIS in response to cold exposure or stress.	4.04	3	1
Carbohydrate Inducible Hyperlipemia [description not available]	1.95	1	0
Hyperchylomicronemia Late Onset [description not available]	1.95	1	0
Hyperlipoproteinemia Type IV A hypertriglyceridemia disorder, often with autosomal dominant inheritance. It is characterized by the persistent elevations of plasma TRIGLYCERIDES, endogenously synthesized and contained predominantly in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins). In contrast, the plasma CHOLESTEROL and PHOSPHOLIPIDS usually remain within normal limits.	1.95	1	0
Dermatoses [description not available]	1.99	1	0
Skin Diseases Diseases involving the DERMIS or EPIDERMIS.	1.99	1	0
Blood Pressure, High [description not available]	3.34	1	1
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	3.34	1	1

inositol niacinate

Cross-References

Synonyms (96)

Research Excerpts

Bioavailability

Dosage Studied

Occurs in Manufacturing (5 Product(s))

Product Categories

Products

Drug Classes (1)

Bioassays (4)

Research

Studies (39)

Market Indicators

Research Demand Index: 30.52

Study Types